{
    "1": {
        "question": "What are the three key components integrated in the prediction model for CRC onset?",
        "options": {
            "A": "Protein risk score (ProS), polygenic risk score (PRS), and QCancer-15 risk score (QCancer-S)",
            "B": "Blood pressure, cholesterol levels, and BMI",
            "C": "Smoking status, alcohol intake, and family history",
            "D": "Age, gender, and ethnicity",
            "E": "Exercise frequency, diet, and stress levels",
            "F": "I don't know"
        }
    },
    "2": {
        "question": "In the study, what was the combined model's C-statistic in the validation cohort?",
        "options": {
            "A": "0.71",
            "B": "0.75",
            "C": "0.79",
            "D": "0.84",
            "E": "0.69",
            "F": "I don't know"
        }
    },
    "3": {
        "question": "Which stage of the study identified 421 differentially expressed plasma proteins?",
        "options": {
            "A": "Exploratory stage",
            "B": "Validation stage",
            "C": "Discovery stage",
            "D": "Experimental stage",
            "E": "Implementation stage",
            "F": "I don't know"
        }
    },
    "4": {
        "question": "Which proteins were found to have an inverse association with incident CRC in the validation cohort?",
        "options": {
            "A": "243 upregulated proteins",
            "B": "253 measured proteins",
            "C": "88 validated proteins",
            "D": "13 proteins with HR < 1",
            "E": "15 protein biomarkers",
            "F": "I don't know"
        }
    },
    "5": {
        "question": "According to the study, what is the median follow-up time for the validation cohort?",
        "options": {
            "A": "8.5 years",
            "B": "10 years",
            "C": "13.05 years",
            "D": "15 years",
            "E": "12.38 years",
            "F": "I don't know"
        }
    },
    "6": {
        "question": "How does the performance of the combined model compare to QCancer-S alone in the training cohort?",
        "options": {
            "A": "It is worse",
            "B": "It shows significantly improved performance",
            "C": "It is the same",
            "D": "Performance varies by cohort",
            "E": "It shows slightly diminished performance",
            "F": "I don't know"
        }
    },
    "7": {
        "question": "Which model had the highest C-statistic in the training cohort according to the study?",
        "options": {
            "A": "QCancer-S",
            "B": "ProS",
            "C": "LDpred2-auto",
            "D": "LDpred2-grid combined with QCancer-S",
            "E": "PRS alone",
            "F": "I don't know"
        }
    },
    "8": {
        "question": "What age is recommended to start CRC screening for participants with high PRS according to the study?",
        "options": {
            "A": "50 years old",
            "B": "41 years old",
            "C": "46 years old",
            "D": "Before 40 years old",
            "E": "60 years old",
            "F": "I don't know"
        }
    },
    "9": {
        "question": "Which protein is a member of the trefoil family mentioned in the study?",
        "options": {
            "A": "IGFBP4",
            "B": "TFF1",
            "C": "LTBP2",
            "D": "PZP",
            "E": "SELL",
            "F": "I don't know"
        }
    },
    "10": {
        "question": "What benefit does the decision curve analysis suggest the combined model has over the QCancer-S alone model?",
        "options": {
            "A": "Lower cost",
            "B": "Greater net benefit",
            "C": "Higher sensitivity",
            "D": "Easier implementation",
            "E": "More thorough data collection",
            "F": "I don't know"
        }
    },
    "11": {
        "question": "What statistical method was used to select the final 15 protein biomarkers?",
        "options": {
            "A": "Chi-square test",
            "B": "K-means clustering",
            "C": "LASSO-Cox regression",
            "D": "ANOVA",
            "E": "T-test",
            "F": "I don't know"
        }
    },
    "12": {
        "question": "According to the study, what is the C-statistic for the combined model in male participants of the training cohort?",
        "options": {
            "A": "0.65",
            "B": "0.71",
            "C": "0.77",
            "D": "0.64",
            "E": "0.84",
            "F": "I don't know"
        }
    },
    "13": {
        "question": "What was the criteria for judging a protein to be a valid predictor of CRC?",
        "options": {
            "A": "Proteins with Log2 FC < 0 only",
            "B": "Proteins with Log2 FC > 1 and FDR < 0.01",
            "C": "Consistent direction of effect and P < 0.05 in validation",
            "D": "Proteins associated with other cancers",
            "E": "Proteins identified only in the discovery stage",
            "F": "I don't know"
        }
    },
    "14": {
        "question": "What is the median age for incident CRC cases in the study?",
        "options": {
            "A": "50 years",
            "B": "58 years",
            "C": "62 years",
            "D": "64 years",
            "E": "61 years",
            "F": "I don't know"
        }
    },
    "15": {
        "question": "In the study, what was the observed number of false-positives reduced per 100 individuals using the combined model?",
        "options": {
            "A": "5 fewer false-positives",
            "B": "10 fewer false-positives",
            "C": "14 fewer false-positives",
            "D": "24 fewer false-positives",
            "E": "21 fewer false-positives",
            "F": "I don't know"
        }
    },
    "16": {
        "question": "What risk score showed the greatest increase in risk for CRC in the high-risk group compared to the medium-risk group?",
        "options": {
            "A": "Protein risk score",
            "B": "Polygenic risk score",
            "C": "QCancer-S",
            "D": "Combined risk score",
            "E": "Age-related score",
            "F": "I don't know"
        }
    },
    "17": {
        "question": "How many differentially expressed plasma proteins were downregulated in the discovery stage?",
        "options": {
            "A": "421",
            "B": "243",
            "C": "178",
            "D": "100",
            "E": "150",
            "F": "I don't know"
        }
    },
    "18": {
        "question": "What does the study propose as the personalized initial screening age for participants with high ComS risk?",
        "options": {
            "A": "45 years old",
            "B": "50 years old",
            "C": "53 years old",
            "D": "After 60 years old",
            "E": "Before 40 years old",
            "F": "I don't know"
        }
    },
    "19": {
        "question": "What is the significance level used in the study for multiple testing correction?",
        "options": {
            "A": "P < 0.1",
            "B": "FDR < 0.05",
            "C": "P < 0.01",
            "D": "P < 0.05",
            "E": "P < 0.1",
            "F": "I don't know"
        }
    },
    "20": {
        "question": "Among which group did the combined model achieve the highest C-statistic for rectal cancer in the training cohort?",
        "options": {
            "A": "Overall population",
            "B": "Females",
            "C": "Males",
            "D": "Participants with screening history",
            "E": "Participants without family history",
            "F": "I don't know"
        }
    },
    "21": {
        "question": "What protein among the selected biomarkers is associated with favorable prognosis for rectal cancer patients in response to chemoradiation?",
        "options": {
            "A": "IGF2R",
            "B": "ADGRG2",
            "C": "WFDC2",
            "D": "PZP",
            "E": "CR2",
            "F": "I don't know"
        }
    },
    "22": {
        "question": "How many proteins from the discovery stage were validated in the UK Biobank cohort?",
        "options": {
            "A": "421",
            "B": "243",
            "C": "253",
            "D": "88",
            "E": "75",
            "F": "I don't know"
        }
    },
    "23": {
        "question": "What proportion of the UKBB population was categorized as having a heavy alcohol consumption?",
        "options": {
            "A": "10%",
            "B": "30%",
            "C": "3.7%",
            "D": "5.1%",
            "E": "20%",
            "F": "I don't know"
        }
    },
    "24": {
        "question": "What metric did the study primarily use to measure model discrimination in CRC prediction?",
        "options": {
            "A": "Sensitivity",
            "B": "Specificity",
            "C": "C-statistic",
            "D": "F1-score",
            "E": "Precision",
            "F": "I don't know"
        }
    },
    "25": {
        "question": "What percentage of the validation cohort were diagnosed with CRC during follow-up?",
        "options": {
            "A": "1.4%",
            "B": "2.6%",
            "C": "3.5%",
            "D": "5%",
            "E": "1.9%",
            "F": "I don't know"
        }
    },
    "26": {
        "question": "In the study, which combined score had the most significant difference compared to the medium risk group in terms of years earlier for CRC risk?",
        "options": {
            "A": "High QCancer-S",
            "B": "High ProS",
            "C": "High PRS",
            "D": "High ComS",
            "E": "Medium ProS",
            "F": "I don't know"
        }
    },
    "27": {
        "question": "Which factor was NOT coded based on the baseline characteristics included in QCancer-15 predictors?",
        "options": {
            "A": "Body mass index (BMI)",
            "B": "Alcohol intake",
            "C": "Geographical region",
            "D": "Diet",
            "E": "Family history of CRC",
            "F": "I don't know"
        }
    },
    "28": {
        "question": "Which C-statistic value indicated the best performance of the LDpred2 model in the training cohort?",
        "options": {
            "A": "0.68",
            "B": "0.74",
            "C": "0.71",
            "D": "0.79",
            "E": "0.82",
            "F": "I don't know"
        }
    },
    "29": {
        "question": "What method was used to impute missing protein measurements in the UK Biobank?",
        "options": {
            "A": "Linear regression estimation",
            "B": "Median imputation",
            "C": "Replaced by mean values",
            "D": "K-nearest neighbors",
            "E": "Maximum likelihood estimation",
            "F": "I don't know"
        }
    },
    "30": {
        "question": "According to the study, what was the risk enhancement period (RAP) in years for the high PRS group compared to the medium PRS group?",
        "options": {
            "A": "8.9 years earlier",
            "B": "27.5 years earlier",
            "C": "17.9 years earlier",
            "D": "4.7 years earlier",
            "E": "4.4 years later",
            "F": "I don't know"
        }
    },
    "31": {
        "question": "What is the main advantage of integrating proteomic profiling with PRS and QCancer-15?",
        "options": {
            "A": "Cost-effectiveness of cancer tests",
            "B": "Improved clinical outcomes and risk stratification",
            "C": "Swifter recovery rates post-diagnosis",
            "D": "Lower rates of false negatives",
            "E": "Increased specificity in protein detection",
            "F": "I don't know"
        }
    },
    "32": {
        "question": "In the decision curve analysis, what net benefit did the combined model achieve at a risk probability of 1% for the whole population?",
        "options": {
            "A": "0.62%",
            "B": "0.71%",
            "C": "0.10%",
            "D": "0.24%",
            "E": "0.65%",
            "F": "I don't know"
        }
    },
    "33": {
        "question": "What was the cumulative risk for the high ComS group reaching similar CRC risk to the general population age 50?",
        "options": {
            "A": "41 years old",
            "B": "47 years old",
            "C": "Above 60 years old",
            "D": "Less than 40 years old",
            "E": "50 years old",
            "F": "I don't know"
        }
    },
    "34": {
        "question": "How many participants in the validation cohort were identified as having a family history of CRC?",
        "options": {
            "A": "81 participants",
            "B": "17 participants",
            "C": "428 participants",
            "D": "633 participants",
            "E": "502 participants",
            "F": "I don't know"
        }
    },
    "35": {
        "question": "When were blood samples collected from participants for the study?",
        "options": {
            "A": "At diagnosis",
            "B": "At every follow-up",
            "C": "Upon study completion",
            "D": "At enrollment",
            "E": "At screening meetings",
            "F": "I don't know"
        }
    },
    "36": {
        "question": "According to the study, how much earlier do high ComS participants reach equivalent CRC risk compared to medium ComS participants?",
        "options": {
            "A": "5.7 years",
            "B": "17.9 years",
            "C": "12.4 years",
            "D": "27.5 years",
            "E": "6.3 years",
            "F": "I don't know"
        }
    },
    "37": {
        "question": "What percentage of the study population did NOT have any record of alcohol consumption?",
        "options": {
            "A": "12%",
            "B": "23%",
            "C": "8.6%",
            "D": "5%",
            "E": "15%",
            "F": "I don't know"
        }
    },
    "38": {
        "question": "For the protein risk score (ProS), what is the risk advancement period (RAP) compared to the medium group?",
        "options": {
            "A": "8.9 years later",
            "B": "4.7 years earlier",
            "C": "15.2 years earlier",
            "D": "4.4 years later",
            "E": "17.9 years earlier",
            "F": "I don't know"
        }
    },
    "39": {
        "question": "What method was used for protein measurement in the discovery cohort?",
        "options": {
            "A": "Western Blotting",
            "B": "Mass Spectrometry",
            "C": "Olink Proximity Extension Assay",
            "D": "High-performance liquid chromatography",
            "E": "RNA sequencing",
            "F": "I don't know"
        }
    },
    "40": {
        "question": "Which strategy did the study employ to ensure the stability of its CRC proteomic profile findings across populations?",
        "options": {
            "A": "One-stage analysis",
            "B": "Comparative genomics",
            "C": "Two-stage design",
            "D": "Randomized controlled trial",
            "E": "Clustering analysis",
            "F": "I don't know"
        }
    },
    "41": {
        "question": "Which protein is considered to act as an oncogene in CRC development according to the study?",
        "options": {
            "A": "PON3",
            "B": "TFF1",
            "C": "SELL",
            "D": "LTBP2",
            "E": "WFDC2",
            "F": "I don't know"
        }
    },
    "42": {
        "question": "What is the main reason the UK Biobank was chosen for this study?",
        "options": {
            "A": "Their focus on lung cancer",
            "B": "Its large population sample size and representation",
            "C": "Its emphasis on environmental factors",
            "D": "Their contribution to psychological studies",
            "E": "Their archival tissue samples",
            "F": "I don't know"
        }
    },
    "43": {
        "question": "What is the risk advancement period (RAP) for high PRS participants according to the study?",
        "options": {
            "A": "4.4 years later",
            "B": "8.93 years later",
            "C": "27.52 years earlier",
            "D": "17.87 years earlier",
            "E": "4.67 years earlier",
            "F": "I don't know"
        }
    },
    "44": {
        "question": "Which gender ratio is observed in CRC incident cases according to table 1 of the study?",
        "options": {
            "A": "More females than males",
            "B": "Equal distribution",
            "C": "More males than females",
            "D": "Predominantly female",
            "E": "Predominantly male",
            "F": "I don't know"
        }
    },
    "45": {
        "question": "What reduction in unnecessary colonoscopies does the combined model yield per 10,000 participants, compared to not intervening?",
        "options": {
            "A": "100 fewer colonoscopies",
            "B": "500 fewer colonoscopies",
            "C": "1000 fewer colonoscopies",
            "D": "62 to 71 net fewer colonoscopies without increase in false-positives",
            "E": "10 fewer colonoscopies",
            "F": "I don't know"
        }
    },
    "46": {
        "question": "Which model resulted in greater net benefit when considering entire populations?",
        "options": {
            "A": "ComS alone model",
            "B": "ProS model",
            "C": "PRS alone model",
            "D": "Combined model (QCancer-S + PRS + ProS)",
            "E": "QCancer-S alone model",
            "F": "I don't know"
        }
    },
    "47": {
        "question": "Which protein was reported to have elevated mRNA expression in CRC tissues?",
        "options": {
            "A": "WFDC2",
            "B": "TFF1",
            "C": "PZP",
            "D": "TNXB",
            "E": "APLP1",
            "F": "I don't know"
        }
    },
    "48": {
        "question": "How was the data for polygenic risk scores (PRS) obtained according to the study?",
        "options": {
            "A": "Provided by clinical trials",
            "B": "Estimated through machine learning",
            "C": "From largest trans-ancestry CRC meta-GWAS and Bayesian approach",
            "D": "Inferred genetically from random samples",
            "E": "Taken from local health registries",
            "F": "I don't know"
        }
    },
    "49": {
        "question": "In the study, what is indicated for participants in the high ProS group regarding CRC screening age?",
        "options": {
            "A": "Start screening at age 50",
            "B": "Begin screening at age 47",
            "C": "Screen at age 46",
            "D": "Defer screening until after 60",
            "E": "Screen immediately",
            "F": "I don't know"
        }
    },
    "50": {
        "question": "The inclusion of geographical region in the QCancer-15 risk score is done to improve which aspect of the model?",
        "options": {
            "A": "Generalizability to non-UK populations",
            "B": "Simplification of the model",
            "C": "Model precision",
            "D": "Generalizability to UK populations",
            "E": "Data reduction",
            "F": "I don't know"
        }
    }
}